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ABSTRACT
Objetive: To identify potential clinical and epidemiological predictors of long-term respon-
se to lithium treatment. Methods: A total of 40 adult outpatients followed in an university 
hospital, with confirmed diagnosis of bipolar disorder and with history of lithium use for at 
least a six months period, had their response to this medication assessed through the use of a 
standardized instrument. The ALDA scale is based on retrospective clinical data, in our study 
assessed through a thoroughly reviewed of the medical charts, and is used to evaluate the 
clinical improvement with the treatment (Criterion A), corrected by the acknowledgement 
of possible confounding factors, such as duration of the treatment, compliance and conco-
mitant use of additional medications (Criterion B), in order to estimate the response that can 
be specifically attributable to lithium. Results: Our study found an inverse relation between 
the number of mood episodes with psychotic symptoms and lithium treatment outcome. 
Conclusion: The results reinforce the hypothesis that lithium seems to be less efficacious in 
patients with bipolar disorder who present psychotic symptoms. 
RESUMO
Objetivo: Identificar potenciais preditores clínicos e epidemiológicos de resposta terapêutica ao 
uso prolongado de lítio. Métodos: Um total de 40 pacientes adultos em tratamento ambulatorial 
em um hospital universitário, com diagnóstico confirmado de transtorno afetivo bipolar e histó-
ria de pelo menos seis meses de uso de lítio, teve sua resposta a essa medicação avaliada com 
a utilização de um instrumento padronizado. A escala ALDA leva em consideração informações 
clínicas obtidas de forma retrospectiva, em nosso estudo, por meio de minuciosa revisão dos 
prontuários médicos, para julgar a melhora clínica obtida com o tratamento (Critério A), corrigida 
pela identificação de possíveis fatores confundidores, tais como duração do tratamento, adesão 
e uso concomitante de outras drogas (Critério B), de forma a estimar a resposta que pode ser atri-
buída especificamente ao uso do lítio. Resultados: Nosso estudo encontrou uma relação inversa 
entre o número de episódios de humor com a presença de sintomas psicóticos e o desfecho no 
tratamento com lítio. Conclusão: Esses resultados reforçam a hipótese de que o lítio parece ser 
menos eficaz em pacientes com transtorno afetivo bipolar que manifestam sintomas psicóticos.
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INTRODUCTION
Bipolar disorder (BD) is a chronic and severe mental illness, 
with an estimated prevalence of 1% in the general popula-
tion1-4. The first mood episodes usually appears in adolescen-
ce or early adulthood, between 20 and 30 years of age5, and 
the most prevalent clinical form of the disorder is the occur-
rence of mania or hypomania, interspersed with episodes 
of depression and periods of euthymia. Taking in account 
patients with subthreshold mood symptoms, the prevalen-
ce of bipolar spectrum disorders in the community may rise 
up to 6.4%6. The disorder is strongly associated with reduced 
quality of life, high degree of impairment, disability and hi-
gher health care costs7-9. Psychiatric comorbidity in BD is also 
significant, with a lifetime prevalence of 65% for other Axis-I 
(DSM) disorders10.
Since the famous paper from Cade (1949), in which he 
describes the use of lithium in patients with BD, many stu-
dies have explored the pharmacological treatment options 
for acute mania, depression, and BD maintenance. Still, con-
sidering the myriad of treatment alternatives with Food and 
Drug Administration (FDA) approval, lithium even now stan-
ds as a major option in bipolar maintenance11. Lithium recei-
ved the FDA approval for the prophylactic treatment of BP 
in 1974, but only in 1994 the first study to assess its efficacy 
using a control group was published12. Later, in 2000, Bow-
den et al., published the first randomized double blind study 
with lithium against placebo13.
In this context, the attempts to identify possible predic-
tors to lithium response date back to the first publications 
involving its prophylactic use in mood disorders. Since then, 
many studies explored the predictive power of a number of 
variables, with controversial results14. Nevertheless, available 
data in the literature suggest that lithium therapy seems to 
be more effective in patients with bipolar disorder presen-
ting the so called “core phenotype”, that is, with an episodic 
course, family history of BD, family history of lithium respon-
se, absence of rapid cycling and low comorbidity rate15. Fur-
thermore, patients with atypical features, including mood 
incongruent psychosis, mixed states, rapid cycling, and the 
presence of psychiatric comorbidity, seem to have lower ra-
tes of response to lithium therapy16-19.
Concerning specifically the presence of psychotic symp-
toms in BD, more than half of the patients with BD develop 
psychotic symptoms at some point of their lives18, and the 
hypothesis that patients with psychotic features, like para-
noid delusion and other formal thought disorder, have worst 
response to prophylactic lithium is old17. However, the at-
tempts to confirm the predictive value of psychotic symp-
toms on the outcome of patients with BD and treated with 
lithium showed mixed and inconclusive results14. 
And important aspect involving the predictive value of 
psychotic symptoms in BD concerns the definition of psycho-
sis. In the most frequently adopted model, the psychotic 
symptoms are divided in mood congruent or mood incon-
gruent. Some data in the literature point to worst treatment 
outcomes when mood incongruent psychosis is present14, 
what occurs in up to 55% of the patients with BD20. 
Nevertheless, the literature shows no universally accep-
ted definition of mood incongruent psychosis and even the 
identification of psychotic features in patients with BD may 
be challenging21. The most commonly adopted definition in-
cludes symptoms not directly related to mood polarity, like 
the presence of paranoid and reference delusions, insertion 
of thoughts, and control delusions20,22,23. Mood incongruent 
psychosis is associated with worst psychosocial outcomes, 
possibly because it is related to a higher overall severity of 
the disorder20, though diagnostic issues (such as differential 
diagnosis with schizophrenia spectrum disorders) may also 
play a role. Data in the literature also suggest that these pa-
tients have a poor response to prophylactic lithium24.
This study aims to evaluate, using a standardized method 
(the ALDA scale), the therapeutic response to lithium in the 
maintenance treatment of BD, as to assess possible clinical 
predictors of lithium response. It is important to notice that the 
present paper was conceived within the framework of a lar-
ger genetic study, the ConLiGen, a Genome-wide association 
study (GWAS) with the objective to determine the phenotype 
of lithium response, and of which we represent the Brazilian 
branch. The results presented here are, therefore, a prelimina-
ry analysis of the clinical and sociodemographical data of the 
studied population. The ALDA scale is the instrument adopted 
by the ConLiGen to determine lithium response. 
METHODS
From August 2013 to August 2014, outpatients consecuti-
vely seen at the Unicamp General Hospital Psychiatric Clinic 
with confirmed diagnosis of bipolar disorder (according to 
DSM-IV) and history of current or previous lithium use were 
identified by one of the researchers (LFALS) during their rou-
tine psychiatric consultation and invited to participate in the 
study (which implied in contributing with a blood sample for 
genetic analysis). Only patients with age ≥ 18 years and who 
used lithium for at least a 6 months period were included. 
Patients with intellectual disability, neuropsychiatric symp-
toms possibly related to clinical illness, or inability to unders-
tand the study objectives and to freely consent to participate 
were excluded.
The 40 patients who consented to participate had their 
medical charts thoroughly reviewed in order to collect clini-
cal and sociodemographic data. We used the collected infor-
mation to evaluate lithium response in the maintenance tre-
atment of BD, and to explore possible predictors of lithium 
response. 
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Studied variables
Response to lithium in the maintenance treatment of 
bipolar disorder
It can be challenging to evaluate improvement in patients 
treated in a clinical scenario and not following a strict resear-
ch protocol. For this purpose, the ALDA scale is considered 
a valuable tool, and as far as our knowledge goes, is the only 
instrument that allows to retrospectively assess clinical im-
provement with lithium treatment in a standardized manner.
The ALDA scale is based on retrospective clinical data 
and is divided in two major criteria, namely A and B. Criterion 
A is used to determine the relation between clinical impro-
vement and the treatment (illness activity while in lithium 
use), with scores ranging from 10 (complete response) to 0 
(no change or worsening).
Criterion B concerns possible confounding factors, and is 
used to establish whether there is a causal relationship be-
tween clinical improvement and the treatment. Score 0, 1 or 
2 points for each item: number of episodes before the treat-
ment (B1), frequency of episode before the treatment (B2), 
duration of the treatment (B3), compliance during period(s) 
of stability (B4), and use of additional medications during the 
periods of stability (B5). 
The ALDA scale total score (TA) is obtained by subtracting 
B from A. This way, it allows a categorical approach (above or 
below a cut-off score), or a dimensional approach in the as-
sessment of clinical improvement with lithium treatment25,26. 
The Brazilian version of the ALDA scale adapted to Portugue-
se from the original English instrument within the context of 
this study is provided in the Appendix 1.
To use the ALDA scale, the first step is to determine the 
longest period in which lithium was used and well docu-
mented, with information regarding clinical improvement, 
frequency and duration of mood episodes, total duration of 
the treatment, compliance during treatment (including drug 
levels within therapeutic range), and description of additional 
medication use, including antidepressants and antipsychotics.
In our study, two different researchers (LFALS, JCL) were 
trained using the clinical vignettes from The International 
Consortium on Lithium Genetics (ConLiGen), in order to ca-
librate the scoring of the scale; after that they reviewed the 
clinical charts. This procedure generated a single data bank, 
including all the 40 patients, on which both the researchers 
based their independent score of the ALDA scale. Later they 
debated about their individual ratings aiming for a consensus 
score for each of the ALDA scale items. These consensus sco-
res were used together with the other variables (described 
below) to explore possible predictors of lithium response.
Clinical and sociodemographical variables
Demographic and clinical variables were also obtained in 
this process such as gender, education, age of onset and 
frequency of mood episodes, presence and frequency of 
psychotic symptoms, suicide attempts, hospitalization, elec-
troconvulsive therapy (ECT), use of tobacco, alcohol and 
other drugs, and family history of mental disorder.
The timeframe considered in this study was from the onset 
of the illness (that is, first episode of depression or mania) un-
til the beginning of the interval chosen for the scoring of the 
ALDA scale. This approach was meant to test the predictive po-
wer of the studied variables in regard to the lithium response.
To determine the relation between these variables and 
the scores of the ALDA scale, all data was transformed in 
ranks and submitted to a logistic regression and linear re-
gression (univariate and multivariate models). The significan-
ce level adopted is this study was of 5%.
This study was approved by the Unicamp Research Ethics 
Review Board and a signed consent form was obtained from 
all patients prior to entering the study.
RESULTS
Sample description
Of the 40 patients with BD assessed in this study, 15 were 
males and 25 were females, with a mean age of 40.03 (± 3.08) 
years. Forty percent never got married, and 57.5% never had 
children. Regarding education, most of our patients comple-
ted high school (28.21%) or had incomplete superior educa-
tion (23.08%), with a mean of 9.72 (± 4.08) years of scholar-
ship. Only 42.5% could be considered economically active.
Clinical variables
The mean age of onset of mood symptoms was 24.18 
(± 9.18) years, while the length of the disorder until the cho-
sen period for scoring the ALDA scale was of 12.85 (± 9.18) 
years. Manic symptoms manifested slightly earlier than de-
pressive symptoms (26.55 vs. 28.14 years), but mixed symp-
toms showed the smaller mean age of onset, of 24.55 years. 
A detailed description is shown on Table 1.
Concerning the manifestation of psychosis in BD, our study 
found that 67.5% of the patients (N = 27) presented with psycho-
tic symptoms at some point of their clinical course, including 
delusions, hallucinations and severe disorganized behavior. The 
mean number of mood episodes with psychotic features in this 
group of patients was of 2.77 (± 2.62), with median of 2.00.
In the majority of the patients who presented psychotic 
symptoms at some point (62.96%), such symptoms occurred 
exclusively on manic episodes; only in 3.7% of the cases this 
symptoms occurred exclusively in depressive episodes. In 
33.33% of the patients, the occurrence of psychotic features 
happened in both mania and depression. Most of the patients 
(75.86%) had at least one episode with mood incongruent 
psychotic symptoms, that is, paranoid and reference delusions, 
auditory hallucinations and severe disorganized behavior. 
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Table 1. Clinical features of the mood episodes 
Variable N* Mean S.D. Median Min Max
Age of onset of mood symptoms 40 24.18 9.18 22.00 12.00 49.00
Age at the beginning of the analyzed ALDA period 40 34.90 13.22 32.00 16.00 68.00
Number of manic episodes 40 3.23 3.08 2.00 0.00 13.00
Age of first manic episode 38 26.55 10.50 25.00 14.00 57.00
Number of hypomanic episodes 40 0.53 0.85 0.00 0.00 3.00
Age of First hypomanic episode 13 28.31 9.89 23.00 16.00 44.00
Number of depressive episodes 40 1.53 1.95 1.00 0.00 10.00
Age of first depressive episode 28 28.14 12.23 26.50 12.00 62.00
Number of mixed episodes 40 0.45 1.40 0.00 0.00 7.00
Age of first mixed episode 06 24.50 4.28 22.00 21.00 30.00
Total number of mood episodes 40 5.75 4.46 4.00 1.00 20.00
* N < 40 are due to the nonoccurrence of a given phenomenon or, in some cases, to missing data.
Among the studied variables, there are those that point 
to a more severe clinical course, like history of suicide at-
tempt. In our sample, 22.5% of the patients attempted suici-
de. The mean age of the first suicide attempt was 26.89 years 
(± 12.81). In 28.57% of the cases, the patient had clinical com-
plications with the need to receive medical support.
Other important evidence of clinical severity is the need 
for hospitalization. In the vast majority of the cases (87.5%; N 
= 35), the patient was hospitalized at least once, with a mean 
of 3.4 (± 2.51) hospital admissions per patient, and median 
of 2.0. Finally, 25% had history of ECT treatment for mania, 
depression or mixed states.
Concerning the presence of comorbidity, at least one cli-
nical disease was present in 40% of the cases, and at least 
one other psychiatric disorder was found 57.5% of the cases. 
Substance use disorders, including abusive use and depen-
dence identified by the assistant doctor and reported in the 
medical chart, had a prevalence of 7.69% for alcohol related 
disorders and 10.0% for other drugs. History of current or 
previous tobacco use had a higher prevalence, of about one 
third of the patients (31.58%).
In relation to the instituted maintenance treatment for 
BD, the vast majority of the patients had history of current 
or previous use of more than one pharmacological agent 
beside lithium. The most frequent association was with an-
tipsychotics (95.0%), followed by anticonvulsants (80.0%), 
benzodiazepines (60.0%) and antidepressants (42.5%).
Finally, concerning the presence of family history of 
mental disorder, it is interesting to notice that about 80% of 
the patients had family history of mood disorders, 20% for 
psychotic disorders and 42.5% for some other mental disor-
der, specified or not.
Lithium response
The consensus scores obtained for each of the ALDA scale 
items are presented in the Table 2. 
Table 2. Consensus Scores for the ALDA Scale
Variable N Mean S.D. Median
ALDA A 40 7.00 2.25 7.00
ALDA B1 40 0.50 0.68 0.00
ALDA B2 40 0.38 0.67 0.00
ALDA B3 40 0.53 0.64 0.00
ALDA B4 40 1.05 0.81 1.00
ALDA B5 40 1.78 0.58 2.00
ALDA BT 40 4.23 1.79 4.00
Total ALDA (A-B) 40 2.78 3.08 3.00
The mean duration of the selected intervals to score the sca-
le was 37.35 months (± 39.74), with a median of 24.5 months.
Univariate and multivariate analysis 
Despite the large number of variables we have analyzed, 
only some of them were chosen to integrate the multivaria-
te model. This choice was based in their distribution in the 
studied population and data regarding possible predictors 
to lithium response in the literature. The selected variables 
are exposed in Tables 3 and 4.
Concerning the analysis involving the TOTAL ALDA scores 
(A minus B), we highlight that only four patients had TA ≥ 7, 
the most common cut-off score adopted in studies that use 
the scale. This distribution did not allow the creation of two 
distinct groups (responders vs. non-responders). Thus, we 
adopted a different approach to the data, and used the sco-
res of Criterion A as a continuous variable with the exclusion 
of patients with TB scores > 4, a strategy also adopted by the 
ConLiGen27. As a result, we have obtained a subgroup of 26 
patients, which was analyzed. The rationale for this approach 
is that patients with a high prevalence of confounders, that 
is, with high TOTAL B scores, can compromise the inference 
of causality between clinical improvement and lithium use. 
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Table 3. Clinical predictors of lithium response – univariate linear regression analysis (N = 26)
Variable N DF Parameter estimate Standard error T value PR > |T|
Gender 26 1 0.93464 3.17072 0.29000 0.77070
Years of scholarship 26 1 -0.11763 0.33077 -0.36000 0.72520
Age of onset 26 1 0.25139 0.16900 1.49000 0.14990
Duration of the disorder (Before ALDA) 26 1 -0.00260 0.01380 -0.19000 0.85210
Number of manic episodes 26 1 -0.24399 0.46058 -0.53000 0.60120
Age of first manic episode 26 1 0.04205 0.15313 0.27000 0.78620
Number of depressive episodes 26 1 -0.11900 0.69764 -0.17000 0.86600
History of suicide attempt 26 1 4.49624 3.28098 1.37000 0.18320
Presence of psychotic symptoms (yes or no) 26 1 -3.14379 3.11096 -1.01000 0.32230
Number of mood episodes with psychotic symptoms 26 1 -0.95286 0.47727 -2.00000 0.05730
History of tobacco use 25 1 6.19481 2.73883 2.26000 0.03350
Family history of psychosis 26 1 -6.94318 3.94131 -1.76000 0.09090
History of electroconvulsive treatment 26 1 -0.29323 3.40640 -0.09000 0.93210
Table 4. Patients with total b scores > 4 – Multivariate linear regression analysis (N = 23)*
Variable Parameter estimate Standard error Type II SS F value PR > F R2 parcial
Number of mood episodes with psychotic symptoms -1.24241 0.40396 314.23522 9.46 0.0060 0.2502
History of tobacco use 7.66608 2.41712 334.15917 10.06 0.0048 0.2208
* Selection criteria: stepwise.
The multivariate analysis (N = 23), showed that the num-
ber of mood episodes with psychotic symptoms had and 
inverse relation with clinical improvement, accessed through 
criterion A of the ALDA scale (PE -1.24241). On the other 
hand, we have found a direct relation between clinical im-
provement and history of current or previous tobacco use 
(PE 7.66608).
DISCUSSION
The available data in the literature suggests that the preva-
lence of BD is similar in males and females28, but the clinical 
presentation and the received treatment can differ signifi-
cantly between sexes. Female patients are treated more of-
ten with antidepressants, benzodiazepines, neuroleptics, la-
motrigine and psychotherapy than their male counterparts 
(52). In our sample, concerning lithium response, we have 
not found difference between male and female patients, 
which is in consonance with the data in the literature29,30.
As for the age of onset of mood symptoms, it is conside-
red one of the variables with potential do discriminate pa-
tients with BD in clinical subgroups. Nevertheless, the validity 
of this age based groups is uncertain, and the criteria used to 
discriminate the patients are not consensual5,31. We found no 
relation between age of onset and lithium response. 
Concerning the number and frequency of mood episo-
des, data in the literature suggest that a higher duration of 
the disorder or a higher frequency (number) of mood episo-
des is directly related with morbidity, including higher rates 
of mood cycling and length of the mood episodes32. Howe-
ver, other studies like the systematic review conducted by 
Kleindienst et al. found no relation between the number of 
mood episodes and lithium response in patients with BD14. 
Our results also found no relation between the number of 
episodes of mania, depression, hypomania or mixed states 
and the clinical response to prophylactic lithium.
Bipolar disorder is strongly related with premature mor-
tality, with rates up to 2-3 times higher than in general popu-
lation33. Suicide is the main cause of early mortality in this pa-
tients34. During the course of their lives, approximately 50% 
of the patients with bipolar disorder attempt suicide35, and 
between 11% and 19% commit suicide36. In our study, 22.5% 
of the patients attempted suicide, which is lower than the 
rates reported in the literature. We have not found positive 
or negative relation between history of suicide attempt and 
clinical improvement with prophylactic lithium. 
We have also explored the relation of history of elec-
troconvulsive therapy (ECT) and clinical improvement with 
lithium use. ECT can be a valuable therapeutic option in 
patients with BD, in mania or depressive episodes that are 
refractory to pharmacotherapy. In our sample, 25% of the 
patients had history of ECT treatment, prevalence similar 
with the one found in the literature. We did not found any 
relation between lithium treatment improvement and his-
tory of ECT. 
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Finally, an interesting finding of our study was the positive 
relation between current or previous tobacco use and clinical 
improvement with lithium treatment. Prevalence of tobacco 
use among patients with BD varies between 31.2%37 to 66%38. 
In our study the prevalence was of 31.58%. This result con-
flicts with literature data in which the use of tobacco is more 
frequently associated with worst treatment outcomes and 
higher recurrence and severity rates in patients with BD37.
It is interesting to notice that both tobacco alkaloids and 
lithium reduce the activity of glycogen-synthase-kinase 3 
(GSK3), through the increase of its phosphorylation, thus mo-
dulating cellular inflammatory and apoptotic pathways39,40. 
Nonetheless, we did not perform a detailed characterization 
of tobacco use in the assessed patients and for this reason we 
consider this finding as a secondary outcome which would 
demand a different study design to be properly investigated. 
Psychotic symptoms
Our study found, in the multivariate model, an inverse rela-
tion between the number of mood episode with psychotic 
symptoms and clinical improvement with lithium treatment. 
This finding reinforces the hypothesis that lithium treatment 
tends to be less efficacious in these patients16-19. It is impor-
tant to notice that our variable does not discriminate between 
mood incongruent and congruent psychosis, but 76% of the 
assessed patients with psychotic features had, at some point 
of their clinical course, mood incongruent symptoms.
It is not clear if the presence of this symptoms indicate 
a particular form of BD or simply a non-specific manifes-
tation that follows the subjacent mood symptoms41. It is a 
fact though, that psychotic features indicate a severe clini-
cal presentation of the mood disorder, and is related with 
worst scores in the PANSS, YMRS and GAS scales18. Therefore, 
a possible explanation to this results concern the phenotype 
of the studied population, since what is labeled as bipolar 
disorder today is a significantly larger and more heteroge-
neous group than the manic-depressive disorder patients of 
the recent past42. 
Our study has a number of limitations. First, as any other 
study in which patients are retrospectively assessed throu-
gh the review of their medical charts, the obtained data is 
limited to the quality of these records, and the occurrence 
of missing data or poor descriptions of the patients’ pheno-
menology during mood episodes are not rare. The sample 
size (n = 40) is also small, what can limit the predictive power 
of our conclusions. Hence, it is possible that the relation be-
tween psychosis and worse outcome with lithium treatment 
is incidental, and we could be dealing with a sample of pa-
tients affected with more severe forms of mental disorder. 
Finally, we believe future studies exploring the relation 
between smoking habit and BD, with larger sample sizes 
and a more refined description of tobacco use, could lead 
to some interesting findings, possibly with implication in the 
clinical treatment of these patients.
CONCLUSION
We found that patients with higher number of mood epi-
sodes with psychotic symptoms had worse response to li-
thium maintenance treatment, what is in consonance with 
the available data in the literature.
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APPENDIX 01 – BRAZILIAN VERSION OF THE ALDA SCALE
Critérios Retrospectivos da Resposta Terapêutica de Longo Prazo em Pacientes com Transtorno Afetivo Bipolar
Nome: __________________________ Data: ____________________ Droga: __________________ Avaliador: ________________
Critério A Critérios B
O critério A é usado para determinar associação entre melhora clínica e tratamento. A análise 
deve se referir ao período de tratamento considerado adequado em termos de duração e 
dosagem das medicações. A atividade da doença deve ser avaliada quanto a frequência, 
severidade e duração dos episódios.
10 = Resposta completa. Sem recorrência na vigência de tratamento adequado, sem 
sintomas residuais, recuperação funcional completa
9 = Ótima resposta. Sem recorrência de episódios, porém o paciente pode ter sintomas 
residuais mínimos (ansiedade transitória, alterações no padrão do sono, disforia, 
irritabilidade) sem que seja necessária qualquer intervenção
8 = Ótima resposta. Atividade da doença reduzida mais que 90%
7 = Boa resposta. Atividade da doença reduzida em 80-90%
6 = Boa resposta. Atividade da doença reduzida em 65-80%
5 = Resposta moderada. Atividade da doença reduzida em 50-65%
4 = Resposta moderada. Atividade da doença reduzida em 35-50%
3 = Melhora leve. Atividade da doença reduzida em 20-35%
2 = Melhora leve. Atividade da doença reduzida em 10-20% 
1 = Melhora mínima. Atividade da doença reduzida em 0-10%
0 = Sem mudança ou piora
Total de pontos Critério A: _____ 
Os critérios B são usados para estabelecer se existe uma relação causal entre melhora clínica 
e o tratamento instituído. Atribua 0, 1 ou 2 pontos para cada item.
B1: Número de episódios antes do tratamento:
0 = 4 ou mais episódios
1 = 2 ou 3 episódios
2 = 1 episódio
B1: ____
B2: Frequência dos episódios antes do tratamento:
0 = Moderada a alta, incluindo ciclagem rápida
1 = Baixa, com remissões espontâneas, de três anos ou mais em média
2 = 1 único episódio, risco de recorrência não pode ser estabelecido
B2: ____
B3: Duração do tratamento:
0 = 2 ou mais anos
1 = 1 a 2 anos
2 = Menos que 1 ano
B3: ____
B4: Adesão durante período de estabilidade:
0 = Excelente; documentado por dosagens séricas em nível terapêutico
1 = Boa; mais que 80% das dosagens séricas em nível terapêutico
2 = Pobre; repetidamente abandona tratamento, menos que 80% das dosagens séricas em 
nível terapêutico
B4: ____
B5: Uso de medicação adicional durante período de estabilidade.
0 = Nenhuma, exceto medicação para dormir eventual (uso semanal ou menor frequência); 
sem outros estabilizadores do humor, antidepressivos ou antipsicóticos para controle dos 
sintomas
1 = Antidepressivos em baixa dose ou antipsicóticos “por segurança” ou uso prolongado de 
medicação para dormir
2 = Uso prolongado ou sistemático de antidepressivos ou antipsicóticos
B5: ____
Total de pontos Critérios B: _____
Total de pontos da escala (subtrair B de A): _____
